Compare CRCT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRCT | TBPH |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.1M | 908.9M |
| IPO Year | 2021 | 2013 |
| Metric | CRCT | TBPH |
|---|---|---|
| Price | $5.60 | $17.06 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 606.5K | 350.2K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 22.20% | N/A |
| EPS Growth | 20.69 | ★ 279.13 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $708,780,000.00 | $15,386,000.00 |
| Revenue This Year | $0.08 | $8.46 |
| Revenue Next Year | $0.98 | N/A |
| P/E Ratio | $20.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.74 | $13.08 |
| 52 Week High | $6.90 | $21.03 |
| Indicator | CRCT | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 57.90 |
| Support Level | $5.35 | $16.80 |
| Resistance Level | $5.98 | $17.11 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 40.91 | 21.57 |
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.